晚期非小细胞肺癌原发灶和转移灶ROS1融合基因表达差异分析

目的分析ROS1(c-ros oncogene 1,receptor tyrosine kinase)融合基因在晚期非小细胞肺癌原发灶和转移灶中的差异表达。方法选取非小细胞肺癌原发灶162例,其中配对转移灶139例。采用实时荧光定量PCR检测ROS1融合基因的表达,并分析其在晚期非小细胞肺癌原发灶和转移灶中的表达差异。结果晚期非小细胞肺癌原发灶ROS1融合基因表达阳性率4.3%(7/162),配对原发灶ROS1融合基因表达阳性率2.6%(5/139),配对转移灶融合基因表达阳性率2.2%(3/139);原发灶较转移灶ROS1融合基因检出阳性率显著增高,差异具统计学意义(χ~2=13.517,P=0.000);ROS1融合基因阳性表达在原发灶和转移灶一致性好(κ=0.479,P=0.000)。非小细胞肺癌原发灶中ROS1融合基因表达与病理类型存在密切关系(χ~2=5.195,P=0.031),与患者性别、年龄等不存在明显相关性(P>0.05)。非小细胞肺癌配对原发灶以及转移灶中ROS1融合基因表达与患者性别、年龄、吸烟以及病理类型不存在明显相关性(P>0.05)。结论晚期非小细胞肺癌ROS1融合基因的阳性表达在原发灶中与病理类型有关,其在配对原发灶和转移灶中阳性表达一致性较好,可作为检测ROS1融合基因的备选手段。

Differential Analysis of the ROS1 Fusion Gene Expression in Patients with Advanced Non Small Cell Lung Cancer in Primary and Metastatic Foci

Objective To study the differential expression of ROS (c-ros oncogene 1,receptor tyrosine kinase)fusion gene in primary tumor and metastasis foci of advanced non small cell lung cancer.Methods 162 cases with non-small-cell lung cancer were collected,which paired metastases 139 cases,detected the expression of ROS1 fusion gene using real-time fluorescence quantitative PCR,and analysis the differential expression of the ROS1 in primary and metastatic foci in advanced non-small cell lung cancer.Results The positive rate of ROS1 fusion gene expression in primary tumor with advanced non-small cell lung cancer was 4.3％ (7/162),the positive rate of ROS1 fusion gene expression in metastasis foci was 2.6％ (5/139),the positive expression rate of paired metastasis fusion gene was 2.2％ (3/139);The positive rate of ROS1 fusion gene was significantly higher than that of the primary lesion,and the difference was statistically significant (x2 =13.517,P =0.000);There was a close relationship between ROS1 fusion gene expression and pathological type in non small cell lung cancer (x2 =5.195,P =0.031),and there was no significant correlation with the gender,age,and so on (P ＞ 0.05).There was no significant correlation with the gender,age,smoking and pathological type of the patients in the expression of ROS1 fusion gene in paired primary tumor and metastasis foci of the advanced non-small-cell lung cancer (P ＞ 0.05).Conclusion The positive expression of ROS1 fusion gene in patients with advanced non-small cell lung cancer is related to the pathological type,the consistency of positive expression of ROS1 is good in the primary tumor and metastatic lesions,it can be used as an alternative means of detecting ROS1 fusion gene.